PROTEIN DESIGN AUTOMATION FOR DESIGNING PROTEIN LIBRARIES WITH ALTERED IMMUNOGENICITY
    28.
    发明申请
    PROTEIN DESIGN AUTOMATION FOR DESIGNING PROTEIN LIBRARIES WITH ALTERED IMMUNOGENICITY 审中-公开
    蛋白质设计自动化设计具有改良免疫原性的蛋白质文库

    公开(公告)号:WO2003006154A2

    公开(公告)日:2003-01-23

    申请号:PCT/US2002/000165

    申请日:2002-01-04

    申请人: XENCOR, INC.

    IPC分类号: B01J19/00

    摘要: The present invention relates to the use of a variety of computational methods for modulating the immunogenicity of proteins by identifying and then altering potential amino acid sequences that elicit an immune response in a host organism. In particular, proteins will be screened for MHC binding sequences, T cell epitopes and B cell epitopes.

    摘要翻译: 本发明涉及各种计算方法用于通过鉴定并随后改变在宿主生物体中引发免疫应答的潜在氨基酸序列来调节蛋白质的免疫原性的用途。 特别地,将筛选蛋白质用于MHC结合序列,T细胞表位和B细胞表位。

    IL-18-FC FUSION PROTEINS
    29.
    发明申请

    公开(公告)号:WO2023010021A1

    公开(公告)日:2023-02-02

    申请号:PCT/US2022/074167

    申请日:2022-07-26

    申请人: XENCOR, INC.

    IPC分类号: C07K14/54 A61K38/20 A61P37/02

    摘要: Provided herein are IL18-Fc fusion proteins that include an empty -Fc domain and an IL18 protein connected to another Fc domain. Also provided herein are additional are IL18-Fc fusion proteins such as IL18 x Fab-Fc fusion proteins that include a first monomer containing an IL18 protein connected to a first Fc domain, a second monomer containing a variable heavy chain connected to a second Fc domain, and a variable light chain, such that the variable heavy and light chains form an empty Fab. Various variant IL18 proteins with modifications to reduce heterogeneity and/or reduce affinity/potency and/or improve stability and/or improve production yield are also described.

    IL-7-FC-FUSI0N PROTEINS
    30.
    发明申请

    公开(公告)号:WO2020236655A1

    公开(公告)日:2020-11-26

    申请号:PCT/US2020/033276

    申请日:2020-05-15

    申请人: XENCOR, INC.

    摘要: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.